Dundalk, Ireland
WuXi Biologics is planning to expand its pharmaceutical manufacturing campus in Dundalk, Ireland. A three-story, 110,600-sf vaccine production plant will leverage single-use technologies and processes to optimize efficiency and scalability. A four-story, 62,000-sf facility housing laboratories and administrative offices will also be constructed. The project represents the second phase of development at the site, where WuXi is currently building a $365 million, 522,000-sf manufacturing center that will begin commercial operation in 2022.
Source
